Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment.

Int J Mol Sci · 2025 · PMC12692093 · PMID 41373813

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although OS data were still immature, adjusted analyses suggested a favorable trend for talazoparib.

also in 1,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.